Upadacitinib
M17-380
Phase 3 small_molecule active
Quick answer
Upadacitinib for Atopic Dermatitis is a Phase 3 program (small_molecule) at AbbVie with 3 ClinicalTrials.gov record(s).
Program details
- Company
- AbbVie
- Indication
- Atopic Dermatitis
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active